AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXThe company said its net product revenues rose to $9.9 billion in 2023 from $8.9 billion in 2022. It cited continued uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label expansions into younger age groups as factors.
Key points
AI summaryThe company said its net product revenues rose to $9.9 billion in 2023 from $8.9 billion in 2022. It cited continued uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label expansions into younger age groups as factors.
Vertex said total research and development, acquired in-process research and development (AIPR&D), and selling, general and administrative (SG&A) expenses rose to $4.8 billion in 2023 from $3.6 billion in 2022. The company attributed the increase to higher AIPR&D, the progression of mid- to late-stage clinical programs, and costs to support global launches.
Cash, cash equivalents and marketable securities rose to $13.7 billion as of December 31, 2023 from $10.9 billion at the end of 2022. The company said income from operations and interest income drove the increase, while income tax payments and share repurchases partially offset it.
Vertex said CASGEVY has been approved in the U.S., the E.U., the U.K., Saudi Arabia and Bahrain as a treatment for SCD and TDT in people 12 years of age and older. It also said it plans to submit an NDA for vanzacaftor/tezacaftor/deutivacaftor and VX-548 by mid-2024.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $9.9B
- Operating income
- $3.8B
- Net income
- $3.6B
- EPS
- $13.89
- Operating cash flow
- $3.5B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2023 Net Product Revenues $9.9 billion
The company said its net product revenues rose to $9.9 billion in 2023 from $8.9 billion in 2022. It cited continued uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label expansions into younger age groups as factors.
Source · Based on the MD&A text of the filing
R&D, AIPR&D and SG&A Expenses $4.8 billion
Vertex said total research and development, acquired in-process research and development (AIPR&D), and selling, general and administrative (SG&A) expenses rose to $4.8 billion in 2023 from $3.6 billion in 2022. The company attributed the increase to higher AIPR&D, the progression of mid- to late-stage clinical programs, and costs to support global launches.
Source · Based on the MD&A text of the filing
Vertex cash and marketable securities reach $13.7 billion
Cash, cash equivalents and marketable securities rose to $13.7 billion as of December 31, 2023 from $10.9 billion at the end of 2022. The company said income from operations and interest income drove the increase, while income tax payments and share repurchases partially offset it.
Source · Based on the MD&A text of the filing
CASGEVY approval and 2024 new drug filing plans
Vertex said CASGEVY has been approved in the U.S., the E.U., the U.K., Saudi Arabia and Bahrain as a treatment for SCD and TDT in people 12 years of age and older. It also said it plans to submit an NDA for vanzacaftor/tezacaftor/deutivacaftor and VX-548 by mid-2024.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…